CytoDyn, Inc.
26
1
1
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
26.9%
7 terminated/withdrawn out of 26 trials
65.0%
-21.5% vs industry average
8%
2 trials in Phase 3/4
131%
17 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
Role: lead
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
Role: lead
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Role: lead
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
Role: lead
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
Role: lead
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Role: lead
An Extension of Protocol PRO 140_CD01 Study
Role: lead
A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
Role: lead
PRO 140 in Treatment-Experienced HIV-1 Subjects
Role: lead
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Role: lead
A Compassionate Use Study of Leronlimab in Breast Cancer
Role: lead
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
Role: lead
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
Role: lead
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Role: lead
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
Role: lead
Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
Role: lead
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
Role: lead
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Role: lead
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
Role: lead
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
Role: collaborator